Lilly’s new experimental shot produced 28% weight loss
In a Phase 3 trial, called TRIUMPH-1, participants took 4 milligrams, 9 milligrams or 12 milligrams of Lilly’s retatrutide for about a year and a half. People taking the highest dose lost 28.3% of their body weight, while nearly half of the participants lost more than 30% of their body weight. Those taking the lowest dose still lost 19.0% of their body weight.
- ▪In a Phase 3 trial, called TRIUMPH-1, participants took 4 milligrams, 9 milligrams or 12 milligrams of Lilly’s retatrutide for about a year and a half.
- ▪People taking the highest dose lost 28.3% of their body weight, while nearly half of the participants lost more than 30% of their body weight.
- ▪Those taking the lowest dose still lost 19.0% of their body weight.
4 outlets in our directory ran this story, first to last over 33 hours. Coverage spans 2 points on the political spectrum — 2 lean left, 1 lean right.
- ▪ Is the End of the Obesity Epidemic Near? People Lost Up to 85 Pounds Using New Weight Loss Drug — Reason.com
- ▪ Experimental Drug Yields Dramatic Weight Loss — NYT > Top Stories
- ▪ People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says — NBC News — Health
MarketWatch — Top Stories files mainly under finance. We currently carry 495 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | MarketWatch — Top Stories |
| Canonical URL | https://www.marketwatch.com/story/lillys-new-experimental-shot-produced-28-weight-loss-d569c3dc?mod=mw_rss_topstories |
| Publication time | Thu, 21 May 2026 12:11:00 GMT |
| Retrieval time | 2026-05-21T12:16:11.034Z |
| Last seen | 2026-05-21T12:16:12.634Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 7hq_qh4jc-OV · 4 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
.css-1erd2mv-StyledNewsKitParagraph{word-break:break-word;font-size:calc((16 / var(--article-base-font-size)) * var(--article-text-size-scale) * 1rem);}.css-ucetlp-StyledNewsKitParagraph{margin:0;color:#262626;font-family:Acumin Pro,Arial,Helvetica,sans-serif;font-size:16px;line-height:1.5;font-weight:400;letter-spacing:0px;font-style:normal;text-transform:none;font-stretch:normal;margin-block-end:16px;word-break:break-word;font-size:calc((16 / var(--article-base-font-size)) * var(--article-text-size-scale) * 1rem);}.css-ucetlp-StyledNewsKitParagraph svg{fill:#262626;}.css-ucetlp-StyledNewsKitParagraph fontMetrics{cap-height:696px;ascent:735px;descent:-265px;line-gap:200px;units-per-em:1000px;}Eli Lilly’s next-generation weekly weight-loss shot may be more effective than Zepbound or…
Excerpt limited to ~120 words for fair-use compliance. The full article is at MarketWatch — Top Stories.